Taysha Gene Therapies (NASDAQ:TSHA) CEO Sean Nolan Sells 41,312 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 41,312 shares of the business’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the completion of the sale, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Taysha Gene Therapies Trading Up 0.8%

NASDAQ:TSHA opened at $4.76 on Wednesday. The company has a market capitalization of $1.30 billion, a PE ratio of -14.42 and a beta of 1.02. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The stock’s 50 day moving average price is $5.09 and its 200 day moving average price is $4.08. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Key Stories Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Analyst Upgrades and Downgrades

TSHA has been the subject of a number of research reports. Robert W. Baird upped their target price on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Thursday, October 2nd. Wells Fargo & Company boosted their price target on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a report on Friday, October 17th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Hedge Funds Weigh In On Taysha Gene Therapies

Large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. boosted its stake in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Taysha Gene Therapies in the second quarter worth $11,178,000. Barclays PLC lifted its holdings in Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after acquiring an additional 4,697,611 shares during the period. MPM Bioimpact LLC purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth $6,823,000. Finally, Vestal Point Capital LP grew its stake in shares of Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after purchasing an additional 2,500,000 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.